
COVID-19 Clinical Programme Update
Press release Synairgen plc (‘Synairgen’ or the ‘Company’) COVID-19 Clinical Programme Update SNG001 given Fast Track designation and IND cleared by the US FDA Phase III trial design adapted which will expedite results Phase III trial to commence dosing in …